Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients

Clinical Endocrinology

Volumn 65, Issue 4, 2006, Pages 519-523

  Pötzi, Christian ^a   Moameni, Abbas ^a   Karanikas, Georgios ^a   Preitfellner, Josef ^a   Becherer, Alexander ^a   Pirich, Christian ^a   Dudczak, Robert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 123; IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; CALCULATION; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CASE REPORT; CONTROLLED STUDY; DOSIMETRY; DRUG UPTAKE; EUTHYROIDISM; FEMALE; HUMAN; HYPOTHYROIDISM; MALE; METASTASIS; PRIORITY JOURNAL; THYROID CANCER; THYROIDECTOMY;

AGED, 80 AND OVER; AUTOANTIBODIES; FEMALE; HUMANS; HYPOTHYROIDISM; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOMETRY; RECOMBINANT PROTEINS; STATISTICS, NONPARAMETRIC; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE;

EID: 33748794776     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02626.x     Document Type: Article

References (18)

1. Schlumberger, M.J. (1998) Papillary and follicular thyroid carcinoma. New England Journal of Medicine, 338, 297-306.
2. Maxon, H.R., Thomas, S.R., Hertzberg, V., Kereiakes, J.G., Chen, I.-W., Sperling, M.I. & Saenger, E. (1983) Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. New England Journal of Medicine, 309, 937-941.
3. Dow, K.H., Ferrell, B.R. & Anello, C. (1997) Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid, 7, 613-619.
4. Klein, I. & Ojamaa, K. (2001) Thyroid hormone and the cardiovascular system. New England Journal of Medicine, 344, 501-509.
5. Rudavsky, A.Z. & Freeman, L.M. (1997) Treatment of scan-negative, thyroglobulin-positive metastasis thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone. Journal of Clinical Endocrinology and Metabolism, 82, 11-14.
6. 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. Journal of Clinical Endocrinology and Metabolism, 87, 4063-4068.
7. 131I therapy in thyroid cancer. Journal of Nuclear Medicine, 44, 1069-1071.
8. 131I. Journal of Nuclear Medicine, 44, 1065-1068.
9. Luster, M., Sherman St. I., Skarulis, M.C., Reynolds, J.R., Lassmann, M., Hänscheid, H. & Reiners, Ch (2003) Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 30, 1371-1377.
10. Lorenz-Wawschinek, O., Tiran, B., Eber O. & Langsteger, W. (1994) Photometric determination of iodine in urine. Experimental and Clinical Endocrinology, 102, 57-58.
11. Barbaro, D., Boni, G., Meucci, G., Simi, U., Lapi, P., Orsini, P., Pasquini, C., Piazza, F., Caciagil, M. & Mariani, G. (2003) Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for post surgical remnants ablation and possible role of iodine content in L-Thyroxin in the outcome of ablation. Journal of Clinical Endocrinology and Metabolism, 88, 4110-4115.
12. Löffler, M., Weckesser, M., Francius, C., Kies, P. & Schober, O. (2003) Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma. Nuklearmedizin, 42, 240-243.
13. 131I Diagnostic activities on the biokinetics of thyroid remnants. Journal of Nuclear Medicine, 45, 619-625.
14. 131I for whole-body imaging after stimulation by recombinant human thyrotropin. Clinical and Nuclear Medicine, 28, 93-96.
15. De Keizer, B., Hoekstra, A., Konijnenberg, M.W., DeVos, F., Lambert, B., Van Rijk, P., Lips, C. & De Klerk, J. (2004) Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastasis differentiated thyroid cancer. Journal of Nuclear Medicine, 45, 1549-1554.
16. Robbins, R.J., Larson, S.M., Sinha, N., Shaha, A., Divgi, C., Pentlow, K.S., Ghossein, R. & Tuttle, R.M. (2002) A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. Journal of Nuclear Medicine, 43, 1482-1488.
17. Haugen, B.R., Pacini, F., Reiners, C., Schlumberger, M., Ladenson, P.W., Sherman, St. I., Cooper, D.S., Graham, K.E., Braverman, L.E., Skarulis, M.C., Davies, T.F., DeGroot, L.J., Mazzaferri, E.L., Daniels, G.H., Ross, D.H., Luster, M., Samuels, M.H., Becker, D.V., Maxon, H.R., Cavalieri, R.R., Spencer, C.A., McEllin, K., Weintraub, B.D. & Ridgway, E.C. (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. Journal of Clinical Endocrinology and Metabolism, 84, 3877-3885.
18. Eschmann, S.M., Reischl, G., BilgerK., Kupferschläger, J., Thelen, M.H., Dohmen, B.M., Besenfelder, H. & Bares, R. (2002) Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. European Journal of Nuclear Medicine, 29, 760-767.